What Happened?
Shares of biotech company 10x Genomics (NASDAQ: TXG) jumped 2.8% in the afternoon session after Argus analyst John Eade initiated coverage on the company with a Buy rating.
The new coverage established Argus's formal research tracking of 10x Genomics. An analyst initiation occurs when an investment research firm begins publishing regular analysis and investment recommendations on a security. A Buy rating indicates an expectation that the stock will deliver positive returns or outperform benchmark averages over an investment timeframe. New coverage initiations often draw increased attention from investors, contributing to positive trading momentum.
The shares closed the day at $88.45, up 3.2% from the previous close.
Is now the time to buy 10x Genomics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
10x Genomics’s shares are extremely volatile and have had 59 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 5 days ago when the stock dropped 7.1% on the news that sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies. The Health Care Select Sector SPDR Fund slipped 0.91% in regular trading, according to exchange data. CMS canceled approximately 315,000 enrollments covering over 760,000 individuals following an investigation into unauthorized sign-ups, the agency said in a fact sheet. The administration expects the purge to recoup roughly $2.2 billion in advance premium tax credits, according to CNBC.
Rulemaking records show the agency also paused new broker registrations through February 2027 and will review 419,000 additional enrollees. Because federal premium tax credits flow directly to health plans rather than enrollees, policy terminations immediately cut exchange revenue. Healthcare companies like Centene and Molina write significant marketplace volume, leaving their toplines more exposed to membership purges than commercial peers. Halting broker onboarding also risks crimping sign-ups ahead of open enrollment on November 1. The crackdown shifts the exchange thesis from enrollment growth to regulatory friction. With broker channels restricted and verification tightening, exchange-focused insurers face a shrinking addressable market and higher acquisition costs into the next plan year.
10x Genomics is up 432% since the beginning of the year, and at $88.45 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of 10x Genomics’s shares 5 years ago would now be looking at only $605.62.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
